Novavax, Inc. (NASDAQ: NVAX) shares are trading higher Tuesday after the company announced it entered into a license agreement with Pfizer, Inc. (NYSE: PFE) for use of its Matrix-M adjuvant. Under the ...

Novavax faces plenty of uncertainty related to a deal it signed with a larger company. The biotech's pipeline doesn't look that exciting either. Last year, Novavax signed an agreement with Sanofi, ...

Novavax signed a potentially lucrative deal with a pharmaceutical giant. However, the biotech's core business remains uncertain. There is also plenty of risk with the company's pipeline candidates. 10 ...

・Analysts see greater upside in Novavax, while Moderna carries a ‘Hold’ rating despite stronger gains over the past year. ・Moderna was in focus after updated cancer vaccine data, while Novavax drew ...

Vaccine biotechnology company Novavax (NASDAQ:NVAX) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 66.6% year on year to $147.1 million. Its GAAP profit of $0.11 ...

According to TipRanks.com, Hester is a 4-star analyst with an average return of 13.9% and a 50.0% success rate. Hester covers the Healthcare sector, focusing on stocks such as Telix Pharmaceuticals, ...